Who Is Watching Baxter International in March 2018? For fiscal 2018, Baxter International (BAX) changed its reporting structure from the previous year. The company has two segments—Hospital Products and Renal—with a …
In this study, we found that CtBP represses Bcl-2-associated X protein (Bax) transcription in glucose-rich media by binding to the E-box region of the Bax promoter. Glucose withdrawal leads to the dissociation of CtBP from the Bax promoter …
There’s Netflix, and then there’s everyone else in 2018. The stock is up more than 50% in the first two months of the year after shattering subscription-growth expectations. It’s market capitalisation has soared to US$126bn. That jump easily …
Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and …
After rising 19% yesterday on takeover speculation, shares of Brocade Communications (Nasdaq: BRCD) are flat today. Yesterday, the Wall Street Journal reported that Brocade has quietly put itself up for sale with potential buyers …
Baxter International Inc. BAX reported fourth-quarter 2017 adjusted earnings per share of 64 cents, which beat the Zacks Consensus Estimate by 5 cents and improved from the year-ago quarter’s figure of 57 cents. Baxter has a Zacks Rank …
Equity securities primarily consist of common stock- preferred stock- securities convertible into common stock- or securities or other instruments whose price is linked to the value of common stock. The fund focuses primarily on …
Baxter International Inc : Company provides financial outlook for 2018 and 2020 . Expects to grow sales 3 to 4 percent on a compounded annual basis at constant currency rates from 2016 through 2018 . Expects a 2018 adjusted operating …
Equity securities primarily consist of common stock- preferred stock- securities convertible into common stock- or securities or other instruments whose price is linked to the value of common stock. The fund focuses primarily on …
Baxter International Inc. (BAX) entered a global licensing agreement with Cell Therapeutics, Inc. (CTIC) to jointly develop and commercialize JAK2/FLT3 inhibitor pacritinib that fights against genetic mutations linked to myelofibrosis, leukemia …